Cargando…
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Inhibitors of poly(ADP-ribose) polymerases (PARPs), which play a key role in DNA damage/repair pathways, have been developed as antitumor agents based on the concept of synthetic lethality. Synthetic lethality is the idea that cell death would be efficiently induced by simultaneous loss of function...
Autores principales: | Ohmoto, Akihiro, Yachida, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667784/ https://www.ncbi.nlm.nih.gov/pubmed/29138572 http://dx.doi.org/10.2147/OTT.S139336 |
Ejemplares similares
-
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018) -
Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021) -
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014) -
Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
por: Zheng, Jingcao, et al.
Publicado: (2023)